Keqian Biology released its performance for the first half of the year, with a net profit attributable to the parent company of 220 million yuan, an increase of 44.09%
Keqian Biology released its 2025 semi-annual report, with operating revenue of 487 million yuan, a year-on-year increase of 21.67%; net profit attributable to the parent company was 220 million yuan, a year-on-year increase of 44.09%. The net profit after deducting non-recurring gains and losses was 190 million yuan, a year-on-year increase of 43.12%. Basic earnings per share were 0.47 yuan, benefiting from improved market conditions and increased sales
According to the Zhitong Finance APP, Keqian Biology (688526.SH) released its semi-annual report for 2025, showing an operating income of 487 million yuan, a year-on-year increase of 21.67%. The net profit attributable to shareholders of the listed company was 220 million yuan, a year-on-year increase of 44.09%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 190 million yuan, a year-on-year increase of 43.12%. The basic earnings per share were 0.47 yuan. Due to the improvement in market conditions, the company's sales increased, leading to higher revenue
